Compare Abercrombie & Fitch Co. (ANF) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Heron Therapeutics Inc — how do they compare? Abercrombie & Fitch Co. trades at $93.3 (market cap $4.14B), while Heron Therapeutics Inc trades at $0.4 (market cap $79.52M). The key difference: Abercrombie & Fitch Co. is far larger — about 52.1× Heron Therapeutics Inc's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ANF | HRTX | |
|---|---|---|
Market Cap | $4.14B | $79.52M |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $2.18 |
52-Week Low | $65.61 | $0.39 |
Enterprise Value | $4.81B | $177.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.
The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
